Breaking News, Collaborations & Alliances

BioInvent, Cancer Research UK Sign Manufacturing Pact

Expected to generate approximately $3 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioInvent International AB has entered a production agreement with Cancer Research UK, an independent funder of cancer research, for the production of Hummingbird Bioscience’s anti-HER3 antibody drug HMBD-001 for use within a clinical partnership formed between Cancer Research UK and Hummingbird Bioscience to test the agent in a phase I trial.   Under the agreement, which is expected to generate revenue of approximately SEK 30 million (~$3 million), mostly in 2020, BioInvent will provide H...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters